UniQure Shares Dive After ‘Surprising’ Pivot by FDA on Drug Data
UniQure NV plunged Monday after the drug developer said US regulators deemed the clinical data for its experimental gene-therapy for Huntington’s disease as insufficient.
By Avalon Pernell, Angel Adegbesan · Bloomberg Markets
UniQure NV plunged Monday after the drug developer said US regulators deemed the clinical data for its experimental gene-therapy for Huntington’s disease as insufficient.